Literature DB >> 21915733

Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers.

Meng-xiang Su1, Min-hong Liu, Bin Di, Li-li Huang, Yuan Jiang, Peng-cheng Ma, Tai-jun Hang.   

Abstract

The pharmacokinetic behaviors of the epimers of cefotetan disodium (R-CTT, S-CTT) after a single intravenous injection dose in healthy Chinese volunteers were explored in this study. In an open-label, randomized, three-way, cross-over study, 12 volunteers (6 females and 6 males) received a cross-over fashion doses of 0.5, 1.0, and 2.0 g of cefotetan disodium, separated by washout periods of 7 days. The plasma concentrations of both epimers were measured by validated high-performance liquid chromatography assays. Pharmacokinetic parameters of R-CTT, S-CTT, and total-CTT (R + S mixture) were calculated using a noncompartmental analysis. Generally, the R and S epimers showed different pharmacokinetic behaviors. Following 0.5, 1.0, and 2.0 g doses of cefotetan disodium, values of the total area under the plasma concentration-time curve (AUC(0-∞)) were 124.23 ± 19.54, 231.34 ± 39.34, and 459.09 ± 80.65 for R-CTT; 100.95 ± 14.19, 193.80 ± 30.42, and 372.66 ± 67.32 for S-CTT, respectively. Total body clearance values were 4.13, 4.43, and 4.46 L/h for R-CTT and 5.05, 5.28, and 5.50 L/h for S-CTT, respectively. Mean plasma elimination half-life (t (1/2)) values of R-CTT were 4.16, 4.13, and 4.01 h for 0.5, 1.0, and 2.0 g doses, respectively, and those of S-CTT were 3.15, 3.25, and 3.21 h. There were significant differences in t (1/2) between the two epimers (P < 0.05). The t (1/2) of R-CTT was 28% longer than that of S-CTT, which indicated that the elimination of the S-CTT was greater than that of the R-CTT. All treatments were well tolerated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21915733     DOI: 10.1007/s13318-011-0064-7

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  22 in total

1.  Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project.

Authors:  Dale W Bratzler; Peter M Houck; Chesley Richards; Lynn Steele; E Patchen Dellinger; Donald E Fry; Claudia Wright; Allen Ma; Karina Carr; Lisa Red
Journal:  Arch Surg       Date:  2005-02

2.  Comparative pharmacokinetics of cefotetan and cefoxitin in patients undergoing hysterectomies and colorectal operations.

Authors:  R Quintiliani; C H Nightingale; R C Stevens; W R Outman; P J Deckers; M G Martens
Journal:  Am J Surg       Date:  1988-05-31       Impact factor: 2.565

3.  Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.

Authors:  M J Browning; H A Holt; L O White; S T Chapman; R A Banks; D S Reeves; R A Yates
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

4.  Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study.

Authors:  Shaojun Shi; Yani Liu; Zhongfang Li; Heng Zheng; Yongning Lv; Hui Chen
Journal:  Clin Ther       Date:  2010-09       Impact factor: 3.393

5.  Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers.

Authors:  J Guibert; M D Kitzis; C Yvelin; J F Acar
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

6.  Cefotetan versus conventional triple antibiotic prophylaxis in elective colorectal cancer surgery.

Authors:  Woon Kyung Jeong; Ji Won Park; Seok-Byung Lim; Hyo Seong Choi; Seung-Yong Jeong
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

7.  Clinical and pharmacokinetic study of cefotetan in biliary tract infections: preliminary report.

Authors:  P Cristiano; R Lobello; M R Iovene; G De Ascentis; P Altucci; F Paradisi; L Manguso
Journal:  Chemioterapia       Date:  1988-08

Review 8.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

9.  High-performance liquid chromatographic analysis of cefotetan epimers in human plasma and urine.

Authors:  F Kees; H Grobecker; K G Naber
Journal:  J Chromatogr       Date:  1984-02-10

10.  Cefotetan pharmacokinetics in volunteers with various degrees of renal function.

Authors:  B R Smith; J L LeFrock; P T Thyrum; B A Doret; C Yeh; G Onesti; A Schwartz; J J Zimmerman
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more
  2 in total

1.  Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.

Authors:  Yang Wang; Dan Sun; Yan Mei; Sanlan Wu; Xinlin Li; Sichan Li; Jun Wang; Liuliu Gao; Hua Xu; Yali Tuo
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

2.  Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers.

Authors:  Jian Liu; You Zhai; Lihua Wu; Guolan Wu; Yunliang Zheng; Xingjiang Hu; Jianzhong Shentu
Journal:  Drug Des Devel Ther       Date:  2020-02-13       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.